Selinexor companion diagnostic - Foundation Medicine
Alternative Names: Selinexor - FoundationOne®; Selinexor- FoundationOne® CDx - Foundation MedicineLatest Information Update: 11 Feb 2023
At a glance
- Originator Foundation Medicine
- Developer Foundation Medicine; Karyopharm Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Endometrial cancer
Most Recent Events
- 13 Jan 2023 Foundation Medicine and Karyopharm Therapeutics agree to co-promote and develop Selinexor companion diagnostic for Endometrial cancer
- 05 Jan 2018 Phase-III clinical trials in Endometrial cancer (Diagnosis) in Belgium, Canada, China, Czech Republic, Germany, Greece, Israel, Italy, Spain, Poland, USA (unspecified route)